Cas:71119-11-4 Bucindolol manufacturer & supplier

Chemical Name:Bucindolol

CAS.NO:71119-11-4

Synonyms:Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]-;2-(2-Hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile;Bucindolol;2-(2-Hydroxy-3-{[1-(1H-indol-3-yl)-2-methyl-2-propanyl]amino}propoxy)benzonitrile;2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile;o-(2-Hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile

Molecular Formula:C₂₂H₂₅N₃O₂

Molecular Weight:363.453

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:605.3±55.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.632

PSA:81.07000

Exact Mass:363.194672

LogP:3.19

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-(2-Hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-Hydroxy-3-{[1-(1H-indol-3-yl)-2-methyl-2-propanyl]amino}propoxy)benzonitrile Use and application,o-(2-Hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile technical grade,usp/ep/jp grade.

Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). Bucindolol manufacturer Any drug or medication is composed of two components. Bucindolol supplier The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. Bucindolol vendor Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. Bucindolol factory Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.